Cutia Therapeutics (CUTIA-B, HKEX: 02487) filed its Monthly Return for the period ended 31 March 2026, indicating no changes in authorised, issued or treasury share balances during the month.

Authorised Share Capital • Authorised share count held steady at 2.50 billion ordinary shares with a par value of USD 0.00002 each, keeping total authorised capital at USD 50,000.

Issued and Treasury Shares • Issued shares (excluding treasury) remained at 363.37 million. • Treasury shares were unchanged at 1.36 million, leaving total issued shares at 364.73 million.

Public-Float Status • The company affirmed compliance with the Hong Kong Main Board’s minimum 25% public-float requirement as at 31 March 2026.

Equity Incentive Plans • Pre-IPO Equity Incentive Plan – Share Option Program: 19.18 million options outstanding; up to 18.38 million shares remain issuable, with an additional 18.86 million shares available for future grants. • Post-IPO Equity Incentive Plan: No options outstanding to date; authorisation exists for issuance of up to 30.40 million shares. • Pre-IPO Share Award Program: 18.34 million awards outstanding from the prior month; a further 10.85 million shares remain available for future awards.

Capital Movements • The company reported zero new share issuances, cancellations, or treasury-share transfers in March, resulting in no change to share capital structure.

Compliance Confirmation • Cutia Therapeutics confirmed that all securities-related activities during the month were duly authorised and complied with Hong Kong listing rules and applicable regulations.

The filing underscores a period of capital stability for Cutia Therapeutics, with ample authorised share capacity remaining under its equity incentive schemes and full adherence to public-float requirements.